JP2021519763A5 - - Google Patents

Info

Publication number
JP2021519763A5
JP2021519763A5 JP2020552294A JP2020552294A JP2021519763A5 JP 2021519763 A5 JP2021519763 A5 JP 2021519763A5 JP 2020552294 A JP2020552294 A JP 2020552294A JP 2020552294 A JP2020552294 A JP 2020552294A JP 2021519763 A5 JP2021519763 A5 JP 2021519763A5
Authority
JP
Japan
Prior art keywords
composition
composition according
rdna sequence
bile acids
secondary bile
Prior art date
Application number
JP2020552294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519763A (ja
JPWO2019191694A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025010 external-priority patent/WO2019191694A1/en
Publication of JP2021519763A publication Critical patent/JP2021519763A/ja
Publication of JP2021519763A5 publication Critical patent/JP2021519763A5/ja
Publication of JPWO2019191694A5 publication Critical patent/JPWO2019191694A5/ja
Pending legal-status Critical Current

Links

JP2020552294A 2018-03-29 2019-03-29 炎症性腸疾患を治療するための組成物及び方法 Pending JP2021519763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650002P 2018-03-29 2018-03-29
US62/650,002 2018-03-29
PCT/US2019/025010 WO2019191694A1 (en) 2018-03-29 2019-03-29 Compositions and methods for treating inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
JP2021519763A JP2021519763A (ja) 2021-08-12
JP2021519763A5 true JP2021519763A5 (https=) 2022-04-06
JPWO2019191694A5 JPWO2019191694A5 (https=) 2022-04-06

Family

ID=66429534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552294A Pending JP2021519763A (ja) 2018-03-29 2019-03-29 炎症性腸疾患を治療するための組成物及び方法

Country Status (10)

Country Link
US (1) US20210121505A1 (https=)
EP (1) EP3773643A1 (https=)
JP (1) JP2021519763A (https=)
KR (1) KR20200138333A (https=)
CN (1) CN112118852A (https=)
AU (1) AU2019245430A1 (https=)
BR (1) BR112020019979A2 (https=)
CA (1) CA3095402A1 (https=)
MX (1) MX2020010177A (https=)
WO (1) WO2019191694A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
KR102341323B1 (ko) * 2020-07-07 2021-12-21 한국원자력의학원 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115478031B (zh) * 2022-09-28 2025-04-18 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用
WO2025244478A1 (ko) * 2024-05-24 2025-11-27 서울대학교병원 클로스트리디움 렙텀 균주의 염증성장질환 예방, 치료 및 진단 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035804A1 (ja) * 2011-09-08 2013-03-14 カルピス株式会社 芽胞形成菌の発芽誘起方法
JP5921894B2 (ja) * 2012-01-20 2016-05-24 アサヒカルピスウェルネス株式会社 腸内酪酸産生菌増加剤
CA2899925A1 (en) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
JP6624903B2 (ja) * 2015-11-25 2019-12-25 学校法人東京理科大学 消毒剤及び消毒方法
WO2017160711A1 (en) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
CN110545828A (zh) * 2016-04-19 2019-12-06 基因组研究有限公司 细菌疗法
JP7168558B2 (ja) * 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Clostridium difficile感染症の処置
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法

Similar Documents

Publication Publication Date Title
JP2021519763A5 (https=)
JP2021524476A5 (https=)
RU2020110462A (ru) Композиции и способы для лечения холестатического заболевания
JP2022166039A (ja) 肝内胆汁うっ滞および関連肝疾患の治療
JPWO2019227085A5 (https=)
RU2018135079A (ru) Нейроактивные стероиды, их композиции и применения
JP2012507521A5 (https=)
Tremaine Gastroduodenal Crohn's disease: medical management
JP2020507626A5 (https=)
JP2000507938A (ja) 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びnsaidの組合せ
Liu et al. The farnesoid X receptor agonist tropifexor prevents liver damage in parenteral nutrition‐fed neonatal piglets
JPWO2019191694A5 (https=)
Nikolaidis et al. Small-duct primary sclerosing cholangitis. A single-center seven-year experience
EP3538132B1 (en) Rectal insulin for treatment of inflammatory bowel diseases
Chen et al. Statin therapy and gut microbiota
Lemann et al. Intravenous cyclosporine for perianal Crohn's disease (CD)
Safarovich Influence of intestinal microflora on the development of gallstone disease (literature review)
Georganas et al. Relapsing Wegner's granulomatosis: Successful treatment with cyclosporin-A
Ruocco et al. Crohn's disease and its mucocutaneous involvement
Rather et al. Ulcerative colitis and probiotics: An overview.
HK1243646A1 (zh) 用於调节骨密度的方法
US6348495B1 (en) Method for treating celiac disease
CN117625588A (zh) 一种治疗非酒精性脂肪肝的活菌复合物
US20250025495A1 (en) Diagnosis and Treatment of Metabolic Syndrome with Magnesium Compositions
CN102178683A (zh) 牛磺鹅去氧胆酸在保护消化道功能上的应用